Granted Patent
B2
US 12,708,658 · App. 18/784,736 · Granted Aug 18, 2026
Compositions and methods for treating heart failure
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin.
Claims (8)
1 . A method of treating a heart failure patient by neuregulin 1, the method comprising administering neuregulin 1 at an amount of 0.6 or 1.2 ug/kg to the heart failure patient; wherein the patient has been identified for treatment by neuregulin 1 based on a companion diagnostic test; wherein the neuregulin 1 comprises the amino acid sequence of SEQ ID NO: 1.
2 . The method of claim 1 , wherein the companion diagnostic test measures the plasma level of NT-proBNP in the patient.
3 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the plasma level of NT-proBNP≤4000 fmol/ml.
4 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the plasma level of NT-proBNP is between 1600 fmol/ml and 4000 fmol/ml.
5 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the plasma level of NT-proBNP is ≤1600 fmol/ml.
6 . The method of claim 2 , wherein the plasma level is measured by immunoassay.
7 . The method of claim 1 , wherein the companion diagnostic test is evaluating heart function by NYHA heart function classification.
8 . The method of claim 2 , wherein the result of the test is indicative for the treatment by neuregulin 1 when the heart function is NYHA class II or III.
Priority Claims (2)
WO PCT/CN2011/001691
· Oct 10, 2011
· international
WO PCT/CN2011/081699
· Nov 2, 2011
· international
Continuity (4)
References Cited (367)
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 4179337A
· Davis et al.
· 1979
[cited by applicant]
US 4301144A
· Iwashita et al.
· 1981
[cited by applicant]
US 4485045A
· Regen
· 1984
[cited by applicant]
US 4496689A
· Mitra
· 1985
[cited by applicant]
US 4544545A
· Ryan et al.
· 1985
[cited by applicant]
US 4640835A
· Shimizu et al.
· 1987
[cited by applicant]
US 4670417A
· Iwasaki et al.
· 1987
[cited by applicant]
US 4736866A
· Leder et al.
· 1988
[cited by applicant]
US 4791192A
· Nakagawa et al.
· 1988
[cited by applicant]
US 4870009A
· Evans et al.
· 1989
[cited by applicant]
US 4873191A
· Wagner et al.
· 1989
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 4980286A
· Morgan et al.
· 1990
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5272065A
· Inouye et al.
· 1993
[cited by applicant]
US 5367060A
· Vandlen et al.
· 1994
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5586110A
· Nakaki et al.
· 1996
[cited by applicant]
US 5641869A
· Vandlen et al.
· 1997
[cited by applicant]
US 5667780A
· Ho et al.
· 1997
[cited by applicant]
US 5686102A
· Gross et al.
· 1997
[cited by applicant]
US 5714385A
· Mather et al.
· 1998
[cited by applicant]
US 5716930A
· Goodearl et al.
· 1998
[cited by applicant]
US 5721139A
· Mather et al.
· 1998
[cited by applicant]
US 5736154A
· Fuisz
· 1998
[cited by applicant]
US 5741511A
· Lee et al.
· 1998
[cited by applicant]
US 5834229A
· Vandlen et al.
· 1998
[cited by applicant]
US 5840525A
· Vandlen et al.
· 1998
[cited by applicant]
US 5840697A
· Blondelle et al.
· 1998
[cited by applicant]
US 5846720A
· Foulkes et al.
· 1998
[cited by applicant]
US 5856110A
· Vandlen et al.
· 1999
[cited by applicant]
US 5859206A
· Vandlen et al.
· 1999
[cited by applicant]
US 5886039A
· Kock et al.
· 1999
[cited by applicant]
US 5906810A
· Turner
· 1999
[cited by applicant]
US 5941868A
· Kaplan et al.
· 1999
[cited by applicant]
US 5968511A
· Akita et al.
· 1999
[cited by applicant]
US 6033660A
· Mather et al.
· 2000
[cited by applicant]
US 6054261A
· Masterson
· 2000
[cited by applicant]
US 6087323A
· Gwynne et al.
· 2000
[cited by applicant]
US 6096873A
· Schaefer et al.
· 2000
[cited by applicant]
US 6121415A
· Godowski et al.
· 2000
[cited by applicant]
US 6136558A
· Ballinger et al.
· 2000
[cited by applicant]
US 6156728A
· Gao et al.
· 2000
[cited by applicant]
US 6162641A
· Goldman et al.
· 2000
[cited by applicant]
US 6169070B1
· Chen et al.
· 2001
[cited by applicant]
US 6197801B1
· Lin
· 2001
[cited by applicant]
US 6252051B1
· Godowski et al.
· 2001
[cited by applicant]
US 6258374B1
· Friess et al.
· 2001
[cited by applicant]
US 6387638B1
· Ballinger et al.
· 2002
[cited by applicant]
US 6399746B1
· Vandlen et al.
· 2002
[cited by applicant]
US 6444642B1
· Sklar et al.
· 2002
[cited by applicant]
US 6589229B1
· Connelly et al.
· 2003
[cited by applicant]
US 6593290B1
· Gao et al.
· 2003
[cited by applicant]
US 6635249B1
· Marchioni et al.
· 2003
[cited by applicant]
US 6750196B1
· Reh et al.
· 2004
[cited by applicant]
US 7037888B1
· Sklar et al.
· 2006
[cited by applicant]
US 7063961B2
· Ballinger et al.
· 2006
[cited by applicant]
US 7115554B1
· Sklar et al.
· 2006
[cited by applicant]
US 7226907B1
· Zhou
· 2007
[cited by applicant]
US 7612164B2
· Zhou
· 2009
[cited by applicant]
US 7686787B2
· Moberg et al.
· 2010
[cited by applicant]
US 7795212B2
· Zhou
· 2010
[cited by applicant]
US 7919098B2
· Zhou
· 2011
[cited by applicant]
US 7964555B2
· Zhou
· 2011
[cited by applicant]
US 8394761B2
· Marchionni et al.
· 2013
[cited by applicant]
US 8476405B2
· Zhou
· 2013
[cited by applicant]
US 8609620B2
· Zhou
· 2013
[cited by applicant]
US 8785387B2
· Zhou
· 2014
[cited by applicant]
US 9012400B2
· Zhou
· 2015
[cited by applicant]
US 9089524B2
· Zhou
· 2015
[cited by applicant]
US 9198951B2
· Caggiano et al.
· 2015
[cited by applicant]
US 9340597B2
· Zhou
· 2016
[cited by applicant]
US 9434777B2
· Zhou
· 2016
[cited by applicant]
US 9555076B2
· Zhou
· 2017
[cited by applicant]
US 9580515B2
· Zhou
· 2017
[cited by applicant]
US 9592339B2
· Zhou
· 2017
[cited by applicant]
US 9655949B2
· Zhou
· 2017
[cited by applicant]
US 9783456B1
· Zhou
· 2017
[cited by applicant]
US 20060160062A1
· Young
· 2006
[cited by applicant]
US 20060199767A1
· Zhou
· 2006
[cited by applicant]
US 20070129296A1
· Zhou
· 2007
[cited by applicant]
US 20070141548A1
· Kohl et al.
· 2007
[cited by applicant]
US 20070190127A1
· Zhou
· 2007
[cited by applicant]
US 20070213264A1
· Zhou
· 2007
[cited by applicant]
US 20080039434A1
· Colli
· 2008
[cited by applicant]
US 20090156488A1
· Zhou
· 2009
[cited by applicant]
US 20110229444A1
· Zhou
· 2011
[cited by applicant]
US 20130143845A1
· Supple et al.
· 2013
[cited by applicant]
US 20140364366A1
· Zhou
· 2014
[cited by applicant]
US 20160152727A1
· Zhou
· 2016
[cited by applicant]
US 20160324876A1
· Zhou
· 2016
[cited by applicant]
US 20170189489A1
· Zhou
· 2017
[cited by applicant]
US 20170360889A1
· Zhou
· 2017
[cited by applicant]
US 20180133291A1
· Zhou
· 2018
[cited by applicant]
AU 6827894A
· 1994
[cited by applicant]
CN 1276381A
· 2000
[cited by applicant]
CN 1138785C
· 2004
[cited by applicant]
CN 1498656A
· 2004
[cited by applicant]
CN 1655804A
· 2005
[cited by applicant]
CN 1715926A
· 2006
[cited by applicant]
CN 1743005A
· 2006
[cited by applicant]
CN 1743006A
· 2006
[cited by applicant]
CN 1768859A
· 2006
[cited by applicant]
CN 1836731A
· 2006
[cited by applicant]
CN 101007027A
· 2007
[cited by applicant]
CN 101310766A
· 2008
[cited by applicant]
CN 101310779A
· 2008
[cited by applicant]
CN 101394861A
· 2009
[cited by applicant]
CN 101636656A
· 2010
[cited by applicant]
CN 102159236A
· 2011
[cited by applicant]
CN 102231987A
· 2011
[cited by applicant]
CN 102470161A
· 2012
[cited by applicant]
CN 103857695A
· 2014
[cited by applicant]
CN 104337813A
· 2015
[cited by applicant]
DE 3218121A1
· 1983
[cited by applicant]
EP 0036676A1
· 1981
[cited by applicant]
EP 0052322A2
· 1982
[cited by applicant]
EP 0058481A1
· 1982
[cited by applicant]
EP 0088046A2
· 1983
[cited by applicant]
EP 0102324A2
· 1984
[cited by applicant]
EP 0143949A1
· 1985
[cited by applicant]
EP 0647449A1
· 1985
[cited by applicant]
EP 0133988A2
· 1995
[cited by applicant]
EP 0142641A2
· 1995
[cited by applicant]
EP 0896586B1
· 2006
[cited by applicant]
EP 1731910A1
· 2006
[cited by applicant]
EP 1187634B1
· 2007
[cited by applicant]
FR 2972328A1
· 2012
[cited by applicant]
JP S607934A
· 1985
[cited by applicant]
JP A2005500025
· 2005
[cited by applicant]
RU 2180843C2
· 2002
[cited by applicant]
RU 2457854C2
· 2012
[cited by applicant]
WO WO1989001489A
· 1989
[cited by applicant]
WO WO1990011354A1
· 1990
[cited by applicant]
WO WO1991001140A1
· 1991
[cited by applicant]
WO WO19920018627
· 1992
[cited by applicant]
WO WO1993004169A1
· 1993
[cited by applicant]
WO WO1994000140
· 1994
[cited by applicant]
WO WO1994026298A1
· 1994
[cited by applicant]
WO WO1995032724
· 1995
[cited by applicant]
WO WO1996015812
· 1996
[cited by applicant]
WO WO1997009425A1
· 1997
[cited by applicant]
WO WO1998048827A1
· 1998
[cited by applicant]
WO WO1999018976A1
· 1999
[cited by applicant]
WO WO1999049062A1
· 1999
[cited by applicant]
WO WO2000037095A1
· 2000
[cited by applicant]
WO WO2000064400A2
· 2000
[cited by applicant]
WO WO2000078347A1
· 2000
[cited by applicant]
WO WO2001064877A2
· 2001
[cited by applicant]
WO WO2001070307A1
· 2001
[cited by applicant]
WO WO2001089568A1
· 2001
[cited by applicant]
WO WO2002024889A2
· 2002
[cited by applicant]
WO WO2002040683A2
· 2002
[cited by applicant]
WO WO2002048191A2
· 2002
[cited by applicant]
WO WO2003035095A1
· 2003
[cited by applicant]
WO WO2003099300A1
· 2003
[cited by applicant]
WO WO2003099320A1
· 2003
[cited by applicant]
WO WO2003099321A1
· 2003
[cited by applicant]
WO WO2003100046A1
· 2003
[cited by applicant]
WO WO2004030716A2
· 2004
[cited by applicant]
WO WO2004030717A2
· 2004
[cited by applicant]
WO WO2004050894A2
· 2004
[cited by applicant]
WO WO2004112763A2
· 2004
[cited by applicant]
WO WO2005018673A1
· 2005
[cited by applicant]
WO WO2007062594A1
· 2007
[cited by applicant]
WO WO2007076701A1
· 2007
[cited by applicant]
WO WO2008028405A1
· 2008
[cited by applicant]
WO WO2008089994A1
· 2008
[cited by applicant]
WO WO2008128161A2
· 2008
[cited by applicant]
WO WO2009033373A1
· 2009
[cited by applicant]
WO WO2010030317A2
· 2010
[cited by applicant]
WO WO2010060265A1
· 2010
[cited by applicant]
WO WO2010060266A1
· 2010
[cited by applicant]
WO WO2010142141A1
· 2010
[cited by applicant]
WO WO2011011388A2
· 2010
[cited by applicant]
WO WO2011091723A1
· 2011
[cited by applicant]
WO WO2011112791A1
· 2011
[cited by applicant]
WO WO2011112864A1
· 2011
[cited by applicant]
WO WO2012012682A2
· 2012
[cited by applicant]
WO WO2013053076A1
· 2013
[cited by applicant]
WO WO2013053158A1
· 2013
[cited by applicant]
WO WO2013053201A1
· 2013
[cited by applicant]
WO WO2014056121A1
· 2014
[cited by applicant]
WO WO2014138502A1
· 2014
[cited by applicant]
WO WO2014187342A1
· 2014
[cited by applicant]
WO WO2015010449A1
· 2015
[cited by applicant]
WO WO2015101182A1
· 2015
[cited by applicant]
WO WO2015101208A1
· 2015
[cited by applicant]
WO WO2016058493A1
· 2016
[cited by applicant]
Bakalets, “Chronic heart deficiency with preserved left ventricle ejection fraction,” Problems of Health and Ecology, Gomel State Medical University, 3(33):7-11 (2012). English abstract.
[cited by applicant]
Balligand et al., Cardiac endothelium and tissue growth, Prog. Cardiovasc. Dis., 39(4):351-360 (1997).
[cited by applicant]
Bradley et al., “Limits of cooperativity in a structurally modular protein: response of the notch ankyrin domain to analogous alanine substitutions in each repeat,” J. Mol. Mol., 324:373-386 (2002).
[cited by applicant]
Britsch et al.., “The ErbB2 and ErbB3 receptors sand their ligand, neregulin-1, are essential for development of the sympathetic nervous system,” Genes Dev., 12:1825-1836 (1998).
[cited by applicant]
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,” Surgery, 88(4):507-516 (1980).
[cited by applicant]
Buonanno et al., “Neuregulin and ErbB receptor signaling pathways in the nervous system,” Curr. Opin. Neurobiol., 11:287-296 (2001).
[cited by applicant]
Cameron, “Recent advances in transgenic technology” Mol. Biotech., 7:253-265 (1997).
[cited by applicant]
Carraway et al., “Neuregulin-2, a new ligand of ErbB/ErbB4-receptor tyrosine kinase,” Nature, 387:512-516 (1997).
[cited by applicant]
Chan et al., 2008, “Identification of Cardiac-Specific Myosin Light Chain Kinase,” Circ. Res., vol. 102:571-580.
[cited by applicant]
Chang et al., “Ligands for ErbB-family receptors encoded by a neuregulin-like gene,” Nature, 387:509-512 (1997).
[cited by applicant]
Chen et al., “Expression and Regulation of Cardiotrophin-1 in Ischemia-1 Reinfusion Cardiac Muscle of Rats and Effect of Neuregulin-1,” J. Appl. Clin. Pediatr., 21(1):29-52 (2006).
[cited by applicant]
Chien et al., “Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response,” FASEB J., Dec. 1991; 5(15):3037-3046.
[cited by applicant]
Chien, “Molecular advances in cardiovascular biology,” Science, 260(5110):916-917 (1993).
[cited by applicant]
Cohen et al., “Emerging technologies for sequencing antisense oligonucleotides: capillary electrophoresis and mass spectrometry,” Adv. Chromatogr., 36:127-162 (1996).
[cited by applicant]
Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 (1985).
[cited by applicant]
Colucci et al., “Pathphysiology of heart failure,” Chapter 13 in Heart Diseases: A textbook of cardiovascular medicine, Braunwald, ed., Saunders, Philadelphia. 1996; 5:394-420.
[cited by applicant]
Corfas et al., “Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia,” Nature Neuroscience, 7(6):575-580 (2004).
[cited by applicant]
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens,” Proc. Natl. Acad. Sci., U.S.A., 80(7):2026-2030 (1983).
[cited by applicant]
Crone et al., “ErbB2 is essential in the prevention of dilated cardiomyopathy,” Nat Med., 8(5):459-465 (2002).
[cited by applicant]
Cronin et al., “Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays,” Hum. Mutat., 7(3):244-255 (1996).
[cited by applicant]
Database Biosis, “Deficient cardiac neuregulin-ErbB signaling in type 2 diabetes, and beneficial effects of treatment with neuregulin-1,” Database accession No. PREV201000179850, Nov. 2009 (2 pages).
[cited by applicant]
Dias et al., “The molecular basis of skeletal muscle differentiation,” Semin Diagn Pathol., Feb. 1994; 11(1):3-14.
[cited by applicant]
Doggen et al., “Deficient cardiac neuregulin-ErbB signaling in type 2 diabetes, and beneficial effects of treatment with neuregulin-1,” Circulation, 82nd Scientific Session of the American-Heart Association, Orlando, Fl…
[cited by applicant]
During et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterizaiton,” Ann. Neurol., 25(4):351-356 (1989).
[cited by applicant]
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proc. Natl. Acad. Sci. U S A., Jun. 1985; 82(11):3688-3692.
[cited by applicant]
Eum et al., “Necrosis and apoptosis: sequence of liver damage following reperfusion after 60 min ischemia in rats,” Biochem. Biophys. Res. Comm., 358:500-505 (2007).
[cited by applicant]
Falls et al., “Neuregulins: functions, forms, and signaling strategies,” Exp. Cell Res., 284(1):14-30 (2003).
[cited by applicant]
Fang et al., “Neuregulin-1 preconditioning protects the heart against ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism,” Chin. Med. J., 123:3597-3604 (2010).
[cited by applicant]
Florini et al., “Stimulation of myogenic differentiation by a neuregulin, glial growth factor 2,” J. Biol. Chem., 271(22):12699-12702 (1996).
[cited by applicant]
Galindo et al., “Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure,” J. Am. Heart Assoc.,3(5):e000773 (2014).
[cited by applicant]
Galindo et al., “Neuregulin as a heart failure therapy and mediator of reverse remodeling,” Curr. Heart Fail. Rep., 11(1):40-49 (2014).
[cited by applicant]
Gao et al., “A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure,” J…
[cited by applicant]
Genbank Accession No. AJ247087, Apr. 15, 2005.
[cited by applicant]
Genbank Accession No. BC_109097; GI:80478928, Nov. 4, 2005.
[cited by applicant]
Genbank Accession No. NM_001110810, Nov. 24, 2007.
[cited by applicant]
Gewirtz et al., “Nucleic acid therapeutics: state of the art and future prospects” Blood, 92(3):712-736 (1998).
[cited by applicant]
Ginn et al., “Gene therapy clinical trials worldwide to 2012—an update,” J. Gene Med., 15:65-77 (2013).
[cited by applicant]
Goodson, in Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984).
[cited by applicant]
Gray H., Gray's Anatomy: The Anatomical Basis of Medicine and Surgery, 1995, Ed. Williams et al., Churchill Livingstone, Edinburgh, pp. 264-254, 298-310 and 739-771.
[cited by applicant]
Griffin et al., “DNA sequencing. Recent innovations and future trends,” Appl. Biochem. Biotechnol., 38(1-2):147-159 (1993).
[cited by applicant]
Gu et al., “Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin,” Cardiovasc. Res., 88(2):334-343 (2010).
[cited by applicant]
Guo et al., “Neuroprotective effects of neuregulin-1 in rat models of focal cerebral ischemia,” Brain Res., 1087:180-185, 2006.
[cited by applicant]
Hein et al., “Altered expression of titin and contractile proteins in failing human myocardium,” J. Mol. Cell Cardiol., 26(10):1291-1306 (1994).
[cited by applicant]
Hervent et al., “Left ventricular diastolic dysfunction in obese diabetic mice is attenuated by pharmacological inhibition of dipeptidyl peptidase IV,” Eur. J. Heart Failure Supplements, 12:S12-S16, Abstract 388, (2013).
[cited by applicant]
Higashiyama et al., “A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4,” J. Biochem., 122:675-680 (1997).
[cited by applicant]
Hijazi et al., “NRG-3 in human breast cancers: activation of multiple erbB family proteins,” Int. J. Oncol., 13:1061-1067 (1998).
[cited by applicant]
Holmes et al., “Identification of heregulin, a specific activator of p185erbB2,” Science, 256:1205-1210 (1992).
[cited by applicant]
Huang et al., “Effects of neuregulin-1 on ventricular remolding in experimental diabetic cardiomyopathy,” Chinese Pharmacological Bulletin, 27(11):1532-1536 (2011) (English abstract).
[cited by applicant]
Huang, “Experimental study of the NRG-1 treatment in diabetic cardiomyopathy rats,” Chinese Master's Theses Full-text Database Medicine and Health Sciences, Feb. 2, 2012, No. 4, E065-60 (English abstract).
[cited by applicant]
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proc. Natl. Acad. Sci. U S A., Jul. 1980; 77(7):4030-4034.
[cited by applicant]
International Search Report for International Application No. PCT/CN2006/03694, dated Apr. 12, 2007.
[cited by applicant]
International Search Report for International Application No. PCT/AU99/01137, Mar. 10, 2000.
[cited by applicant]
International Search Report for International Application No. PCT/CN03/00355, dated Jul. 3, 2003.
[cited by applicant]
Izumo et al., “Calcineurin—the missing link in cardiac hypertrophy,” Nat. Med., 4(6):661-662 (1998).
[cited by applicant]
Jabbour et al., “Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses,” Eur. J. Heart Fail., 13(1):83-92 …
[cited by applicant]
Joliot et al., “Antennapedia homebox peptide regulates neural morphogenesis,” Proc. Natl. Acad. Sci., U.S.A., 88(5):1864-1868 (1991).
[cited by applicant]
Jones et al., “Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis,” J. Biol. Chem.,273(19):11667-11674 (1998).
[cited by applicant]
Kida et al., “Congestive heart failure in type 2 diabetes—clinical features, risk factors, characterization of cardiac function, and survival prognosis,” J. Japan Diab. Soc., 44(11):887-894 (2001). English abstract atta…
[cited by applicant]
Köhler et al., “Continuous cultures of fused cells antibody of predifined specificity,” Nature, 256(5517):495-497 (1975).
[cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes,” Immunol. Today, 4(3):72-79 (1983).
[cited by applicant]
Kuramochi et al., “Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1β/erbB4 signaling,” J. Biol. Chem., 279(49):51141-51147 (2004).
[cited by applicant]
Lakso et al., “Targeted oncogene activation by site-specific recombination in transgenic mice,” Proc. Natl. Acad. Sci., U.S.A., 89(14):6232-6236 (1992).
[cited by applicant]
Langer et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J. Biomed. Mater. Res., Mar. 1981; 15(2):267-277.
[cited by applicant]
Langer et al., “Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review,” J. Macromol. Sci. Rev. Macromol. Chem. Phys., 23(1):61-126 (1983).
[cited by applicant]
Langer, “Controlled release of macromolecules,” Chemtech, 12:98-105 (1982).
[cited by applicant]
Langer, “New methods of drug delivery,” Science, 249(4976):1527-1533 (1990).
[cited by applicant]
Levy et al., “Inhibition of calcification of bioprosthetic heart valves by local controlled-release disphosphonate,” Science, 228(4696):190-192 (1985).
[cited by applicant]
Li et al., “Targeted mutation of the DNA methyltransferase gene results in embryonic lethality,” Cell, 69(6):915-926 (1992).
[cited by applicant]
Li et al., “Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats,” Cardiovascular Diabetolgoy, 10(1):69, pp. 1-8 (2011).
[cited by applicant]
Liu et al., “Effects of neuregulin on Rhesus monkey heart failure induced by rapid pacing,” Sichuan Da Xue Xue Bao Yi Xue Ban, 2009, 40(1):93-96 (in Chinese with English Abstract).
[cited by applicant]
Liu et al., “Neuregulin-1/ErbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy,” J. Am. Coll. Cardiol., 2006, 48(7):1438-1447.
[cited by applicant]
Liu, “Protective effects of neuregulin-1β on chronic contractibility cardiac failure and correlative mechanisms research,” Chinese Master's Thesis Full-text database, Medicine and Health Sciences, Jun. 2010, English abs…
[cited by applicant]
Luo et al., “Computational analysis of molecular basis of 1:1 interactions of NRG-1beta wild-type and variants with ErbB3 and ErbB4,” Proteins, 59(4):742-756 (2005).
[cited by applicant]
Macera et al., 1992, “Localization of the Gene Coding for Ventricular Myosin Regulatory Light Chain (MYL2) to Human Chromosome 12q23-q24.3,” Genomics, vol. 13:829-831; Genbank Accession No. NM00432.
[cited by applicant]
Mahar et al., “Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis and induces antidepressant-lik effects,” PLoS One, 6(10):e26610 (2011).
[cited by applicant]
Mahmood et al., “Selection of the first-time dose in humans: comparison of different approacheds based on interspecies scaling of clearance,” J. Clin. Pharm., 43:692-697 (2003).
[cited by applicant]
Massova et al., “Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding fee energies,” J. Am. Chem. Soc., 121(36):8133-8143 (1999).
[cited by applicant]
Maxam et al., “A new method for sequencing DNA,” Proc. Natl. Acad. Sci., U.S.A., 74(2):560-564 (1977).
[cited by applicant]
MeSH entry for Neuregulin-1, retrieved online from http:www.ncbi.nlm.nih.gov/mesh/68020890, entry dated 2000. Retrieved on Jul. 28, 2021.
[cited by applicant]
Montoliu, “Gene transfer strategies in animal transgenesis” Cloning and Stem Cells, 4(1):39-46 (2002).
[cited by applicant]
Morrison et al., “Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,” Proc. Natl. Acad. Sci., U.S.A., 81(21):6851-6855 (1984).
[cited by applicant]
Naeve et al., “Accuracy of automated DNA sequencing: a multi-laboratory comparison of sequencing results,” Biotechniques, 19(3):448-453 (1995).
[cited by applicant]
Neuberger et al., “Recombinant antibodies possessing novel effector funtions,” Nature, 312(5995):604-608 (1984).
[cited by applicant]
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox,” In Merz and Le Grand (Eds.), The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 491-495…
[cited by applicant]
Niemann, “Transgenic fam animals get off the ground” Transgenic Res., 7:73-75 (1998).
[cited by applicant]
Notice of Allowability mailed Apr. 16, 2010 in U.S. Appl. No. 10/997,167.
[cited by applicant]
Office Action mailed Apr. 29, 2010, in U.S. Appl. No. 11/429,203.
[cited by applicant]
Office Action mailed Dec. 22, 2008 in U.S. Appl. No. 10/997,167.
[cited by applicant]
Office Action mailed Dec. 13, 2007, in U.S. Appl. No. 11/429,203.
[cited by applicant]
Office Action mailed Feb. 22, 2010, in U.S. Appl. No. 11/429,202.
[cited by applicant]
Office Action mailed Feb. 4, 2009, in U.S. Appl. No. 11/429,203.
[cited by applicant]
Office Action mailed Jan. 16, 2007, in U.S. Appl. No. 11/429,202.
[cited by applicant]
Office Action mailed Jan. 3, 2008, in U.S. Appl. No. 11/429,202.
[cited by applicant]
Office Action mailed Jun. 26, 2009 in U.S. Appl. No. 10/997,167.
[cited by applicant]
Office Action mailed Jun. 27, 2008, in U.S. Appl. No. 11/429,203.
[cited by applicant]
Office Action mailed Mar. 7, 2008 in U.S. Appl. No. 10/997,167.
[cited by applicant]
Office Action mailed May 5, 2009, in U.S. Appl. No. 11/429,202.
[cited by applicant]
Office Action mailed Nov. 9, 2009 in U.S. Appl. No. 10/997,167.
[cited by applicant]
Office Action mailed Sep. 17, 2009, in U.S. Appl. No. 11/429,203.
[cited by applicant]
O'Gorman et al., “Recombinase-mediated gene activation and site-specific integration in mammalian cells,” Science, 251(4999):1351-1355 (1991).
[cited by applicant]
Olson et al., “Regulation of muscle transcription by the MyoD family. The heart of the matter,” Circ. Res., 1993, 72(1):1-6.
[cited by applicant]
Parker et al., “p53-independent expression of p21Cipl in muscle and other terminally differentiating cells,” Science, 267(5200):1024-1027 (1995).
[cited by applicant]
Partial European Search Report for European Application No. 08020020.7, Jan. 7, 2009.
[cited by applicant]
PCT International Search Report dated Nov. 29, 2007, in International Application No. PCT/CN2007/002531, filed Aug. 21, 2007.
[cited by applicant]
Pentassuglia et al., “The Role of Neuregulin 1β/ErbB signaling in the heart,” Exp. Cell Res., 315:627-637 (2009).
[cited by applicant]
Physicians' Desk Reference. Medical Economics Data Production Co., Montvale, NJ. 1994; pp. 2314-2320.
[cited by applicant]
Polak et al., 1991, “A Novel Calmodulin Antagonist, CGS 9343B, Modulates Calcium-Dependent Changes in Neurite Outgrowth and Growth Cone Movements,” J. Neurosci., vol. 11(2):534-542.
[cited by applicant]
Prelle et al., “Establishment of pluripotent cell lines from vertebrate species—present status and future prospects” Cells Tissues Organs, 165:220-236 (1999).
[cited by applicant]
Ramachandran et al., Vet. Pathol., 45:698-706 (2008).
[cited by applicant]
Ristevski, “Making better transgenic models” Mol. Biotech., 29:153-163 (2005).
[cited by applicant]
Rumyantsev, “Interrelations of the proliferation and differentiation processes during cardiac myogenesis and regeneration,” Int. Rev. Cytol., 51:186-273 (1977). (2 parts).
[cited by applicant]
Sadick et al., “Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput Kinase receptor activation enzyme-linked immunosorbant assay,” Anal. Biochem., 235:207-214 (1996).
[cited by applicant]
Saiki et al., “Analysis of enzymatically amplified beta-globin and HLA-DQα DNA with allele-specific oligonucleotide probes,” Nature, 324(6093):163-166 (1986).
[cited by applicant]
Saiki et al., “Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes,” Proc. Natl. Acad. Sci. U.S.A., 86(16):6230-6234 (1989).
[cited by applicant]
Sanger et al., “dna sequencing with chain-terminating inhibitors,” Proc. Natl. Acad. Sci., U.S.A., 74(12):5463-5467 (1977).
[cited by applicant]
Sawyer et al., “Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity,” Circulation, 105(13)…
[cited by applicant]
Schaper et al., “Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy,” Circulation, 83(2):504-514 (1991).
[cited by applicant]
Sefton, “Implantable pumps,” Crit. Rev. Biomed. Eng., 14(3):201-240 (1987).
[cited by applicant]
Seguchi et al., 2007, “A Cardiac Myosin Light Chain Kinase Regulates Sarcomere Assembly in the Vertebrate Heart,” The Journal of Clinical Investigation, vol. 117(10):2812-2824.
[cited by applicant]
Sharma et al., 1979, “Preparation and Assay of the Ca2+-Dependent Mudulator Protein,” Adv. Cyclic Nucleotide Res., vol. 10:187-198.
[cited by applicant]
Shyu et al., Neurobio. Aging, vol. 25, pp. 935-944 (2004).
[cited by applicant]
Sidman et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers, Jan. 1983; 22(1):547-556.
[cited by applicant]
Sigma Genosys, “Designing custom peptides,” retrieved from URL: http://www.sigma-genosys.com/peptide_design.asp>, retrieved on Dec. 16, 2004, pp. 1-2.
[cited by applicant]
Simpson et al., “Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines,” Circ. Res.51(6):787-801 (1982).
[cited by applicant]
Slamon et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” N. Engl. J. Med., 344(11):783-792 (2001).
[cited by applicant]
Smith, “Gene transfer in higher animals: theoretical considerations and key concepts” J. Biotechnol., 99:1-22 (2002).
[cited by applicant]
Sobey et al., “Allopurinol and amlodipine improve coronary vasodilatation after myocardial ischaemia and reperfusion in anaesthetized dogs,” Br. J. Pharmacol., 108:342-347 (1993).
[cited by applicant]
Stevenson et al., “Optimizing therapy for complex or refractory heart failure: a management algorithm,” Am. Heart J., 135(6 Pt 2 Su):S293-S309 (1998).
[cited by applicant]
Swynghedauw, “Molecular mechanisms of myocardial remodeling,” Physiol. Rev., 79(1):215-262 (1999).
[cited by applicant]
Takemura, Nihon Kyobu Geka Gakkai, pp. 247-253, 1993 (Abstract Only).
[cited by applicant]
The Fantom Consrtium et al., “The transcriptional landscape of the mammalian genome,” Science, 309:1559-1563 (2005).
[cited by applicant]
Thomas et al., “Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells,” Cell, 51(3):503-512 (1987).
[cited by applicant]
Tsutamoto, “BNP and NT-proBNP as a cardio-renal biomark,” Igaku No Ayumi, 232(5):459-465 (2010). English abstract attached.
[cited by applicant]
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), “Guidance for Industry, estimating the maximum safe starting dose in initial clinical trials fo…
[cited by applicant]
Voet and Voet, Biochemistry, 2nd edition, John Wiley & Sons, Inc., pp. 235-241 (1995).
[cited by applicant]
Wallace et al., 1983, “Assay of Calmodulin by Ca2 -Dependent Phosphodiesterase,” Methods Enzymol, vol. 102:39-47.
[cited by applicant]
Wang et al., “Improvement of cardiac function and reversal of gap junction remodeling by Neuregulin-1β in volume-overloaded rats with heart failure,” J. Geriatr. Cardiol., 9(2):172-179 (2012).
[cited by applicant]
Watson et al., Molecular Biology of the Gene, 4th Edition, The Bejacmin/Cummings Publishing Company, Inc., Menlo Park, CA, p. 224 (1987).
[cited by applicant]
Wells, “Additivity of mutational effects in proteins,” Biochem., 29(37):8509-8517 (1990).
[cited by applicant]
Wilmut et al., “Viable offspring derived from fetal and adult mammalian cells,” Nature, 385(6619):810-813 (1997).
[cited by applicant]
Yarden et al., “Untangling the ErbB signaling network,” Nat. Rev. Mol. Cell Biol., 2(2):127-137 (2001).
[cited by applicant]
Yellon et al., “Myocardial Reperfusion Injury” N. Engl. J. Med., 357:1121-1135 (2007).
[cited by applicant]
Zhao et al., “Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes,” Development, May 1998; 125(10):1899-1907.
[cited by applicant]
Zhao et al., “Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes,” J. Biol. Chem., 273(17):10261-10269 (1998).
[cited by applicant]
Zhou et al., “Retinoid-dependent pathways suppress myocardial cell hypertrophy,” Proc. Natl. Acad. Sci. U S A., Aug. 1, 1995; 92(16):7391-7395.
[cited by applicant]
Wikipedia entry for “Cardiomyopathy,” retrieved from the internet, available as early as Jan. 2021 : <URL: http://en.wikipedia.org/wiki/Cardiomyopathy>.
[cited by applicant]